Case Reports in Oncology (May 2022)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

  • Go Makimoto,
  • Atsushi Shimonishi,
  • Kadoaki Ohashi,
  • Kiichiro Ninomiya,
  • Hisao Higo,
  • Yuka Kato,
  • Masanori Fujii,
  • Toshio Kubo,
  • Eiki Ichihara,
  • Katsuyuki Hotta,
  • Masahiro Tabata,
  • Yoshinobu Maeda,
  • Katsuyuki Kiura

DOI
https://doi.org/10.1159/000524326
Journal volume & issue
Vol. 15, no. 2
pp. 494 – 498

Abstract

Read online

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround time than the conventional test, was launched in Japan as a tepotinib companion test. We report a patient with an advanced MET-mutant NSCLC promptly diagnosed using the AmoyDx® panel and successfully treated with tepotinib. Although the patient’s performance status (PS) worsened due to the rapid tumor progression and lung abscess formation, the tumor shrank immediately after tepotinib treatment with marked PS improvement.

Keywords